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:   T helper 1/2
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:   regulatory T cell
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:   visual analog score

1. INTRODUCTION {#all14073-sec-0006}
===============

Rhinoconjunctivitis and other IgE‐mediated allergies are an increasing disease burden globally.[1](#all14073-bib-0001){ref-type="ref"} Most therapies for allergies are directed at relieving symptoms, but allergen‐specific immunotherapy (AIT) is the only current therapy that modifies the natural course of allergic diseases. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are both proven effective treatments for grass pollen‐induced rhinoconjunctivitis.[2](#all14073-bib-0002){ref-type="ref"}, [3](#all14073-bib-0003){ref-type="ref"}, [4](#all14073-bib-0004){ref-type="ref"} The therapeutic effect is maintained beyond the conclusion of treatment.[5](#all14073-bib-0005){ref-type="ref"}, [6](#all14073-bib-0006){ref-type="ref"}, [7](#all14073-bib-0007){ref-type="ref"} In patients with allergic rhinitis, AIT can prevent the onset of new sensitizations[8](#all14073-bib-0008){ref-type="ref"} and decrease the likelihood of developing asthma.[9](#all14073-bib-0009){ref-type="ref"} The immunomodulatory properties of AIT affect local and systemic immune responses, with an impact on the number and function of mast cells, basophils, antigen‐presenting cells, T cells, and B cells.[10](#all14073-bib-0010){ref-type="ref"}, [11](#all14073-bib-0011){ref-type="ref"}

Allergic patients manifest sensitization by means of allergen‐specific IgE bound to effector cells, particularly mast cells and basophils.[12](#all14073-bib-0012){ref-type="ref"} The underlying mechanism is thought to be a shifted T‐cell balance toward a T helper 2 (Th2) phenotype, and these cells produce interleukin (IL)‐4 and IL‐13 that direct allergen‐specific B cells to produce IgE.[13](#all14073-bib-0013){ref-type="ref"} Furthermore, Th2 cells produce IL‐5 which promotes the involvement of eosinophils in the pathogenesis of allergic diseases.[14](#all14073-bib-0014){ref-type="ref"} In contrast, Th1 responses are promoted by IFN‐γ and skew away from a Th2 phenotype.[15](#all14073-bib-0015){ref-type="ref"} Effective immunotherapy has been shown to reverse the Th2 dominance and to result in anergy of allergen‐specific T cells,[16](#all14073-bib-0016){ref-type="ref"}, [17](#all14073-bib-0017){ref-type="ref"} induction of regulatory T cells (Treg),[18](#all14073-bib-0018){ref-type="ref"}, [19](#all14073-bib-0019){ref-type="ref"}, [20](#all14073-bib-0020){ref-type="ref"}, [21](#all14073-bib-0021){ref-type="ref"} and production of blocking antibodies of the IgG and IgA isotypes.[22](#all14073-bib-0022){ref-type="ref"}, [23](#all14073-bib-0023){ref-type="ref"} Specifically, TGF‐β and IL‐10 produced by Treg are pivotal for the successful immune deviation in AIT.[24](#all14073-bib-0024){ref-type="ref"}, [25](#all14073-bib-0025){ref-type="ref"}

The tolerogenic functions of IL‐10 are extensive, but mainly encompass the inhibition of mast cell activity,[26](#all14073-bib-0026){ref-type="ref"} suppression of IL‐5 production by Th2 cells,[27](#all14073-bib-0027){ref-type="ref"} and cell death induction in eosinophils.[28](#all14073-bib-0028){ref-type="ref"} Furthermore, IL‐10 in combination with IL‐4 and IL‐13 directs B‐cell immunoglobulin class switching to IgG~4~ instead of IgE.[29](#all14073-bib-0029){ref-type="ref"} Indeed, one of the known effects of AIT is an increase in allergen‐specific serum IgG~4~ and an increased serum IgG~4~/IgE antibody ratio that is associated with clinical efficacy.[30](#all14073-bib-0030){ref-type="ref"}

SCIT and SLIT have distinct immunomodulatory capabilities that appear related to the different routes of administration. Sublingual administration results in fewer systemic adverse effects, but some studies indicate diminished clinical and immunological efficacy compared with subcutaneous administration.[2](#all14073-bib-0002){ref-type="ref"}, [31](#all14073-bib-0031){ref-type="ref"} SLIT results in increased numbers of FoxP3^+^ Treg both in the oral epithelium and in the peripheral blood.[23](#all14073-bib-0023){ref-type="ref"}, [32](#all14073-bib-0032){ref-type="ref"} Further systemic alterations are more diverse. Some studies report an initial increase in allergen‐specific IgE serum levels, followed by a decrease after 1 month.[33](#all14073-bib-0033){ref-type="ref"} Furthermore, allergen‐specific IgG~2~, IgG~4,~ and IgA serum levels are reported to increase in as little as 1 day after the start of therapy.[33](#all14073-bib-0033){ref-type="ref"}, [34](#all14073-bib-0034){ref-type="ref"}, [35](#all14073-bib-0035){ref-type="ref"} However, other studies detected no systemic alterations with regard to allergen‐specific lymphoproliferation, cytokine secretion, or Ig serum levels.[36](#all14073-bib-0036){ref-type="ref"}, [37](#all14073-bib-0037){ref-type="ref"}

IgG~2~ and IgG~4~ heavy chain constant regions are encoded by genes in the *IGH* locus. Ig class switching to IgG~2~ and IgG~4~ frequently occurs indirectly following a switch from IgM to the more proximal IgG~3~ and IgG~1~ genes rather than directly from IgM to IgG~2~ or IgG~4~.[38](#all14073-bib-0038){ref-type="ref"} Given the higher loads of somatic hypermutation (SHM) in variable regions of IgG~2~ and IgG~4~ transcripts, it has been suggested that B cells expressing these transcripts have spent more time in the germinal center response.[39](#all14073-bib-0039){ref-type="ref"} In addition, the majority of IgG~2~‐ and IgG~4~‐expressing B cells co‐express CD27, and their frequencies increase with age.[40](#all14073-bib-0040){ref-type="ref"}, [41](#all14073-bib-0041){ref-type="ref"} Hence, it appears that these Ig class switches occur following repeated exposure to the same antigen.

Since AIT has been shown to have long‐lasting beneficial effects, it is important to determine whether this is the result of changes in immunological memory. We here address this question in our cohort of patients with moderate‐to‐severe seasonal allergic rhinitis, studied longitudinally before, during, and after SLIT for grass pollen allergy.[42](#all14073-bib-0042){ref-type="ref"} As published previously,[42](#all14073-bib-0042){ref-type="ref"}, [43](#all14073-bib-0043){ref-type="ref"} SLIT in our cohort resulted in allergic rhinitis symptom relief and conferred significant protection from epidemic thunderstorm asthma, making this an ideal cohort to examine the effects of a 4‐month treatment regimen and the subsequent effects of two further courses of treatment over 3 years on circulating IgE^+^‐ and IgG subclass‐expressing memory B cells and allergen‐specific Ig levels.

2. METHODS {#all14073-sec-0007}
==========

2.1. Study design {#all14073-sec-0008}
-----------------

Using an open‐label longitudinal design (ClinicalTrials.gov identifier: NCT02014623), 29 participants were recruited for treatment with a commercial 5‐grass pollen SLIT tablet (Oralair^®^; Stallergenes) using a 4‐month (May‐September) regimen completed prior to the Australian pollen season, for 3 consecutive years (2014‐2016; subject numbers at each time point shown in Figure [1](#all14073-fig-0001){ref-type="fig"}A). Treatment with Oralair^®^ involved dissolution under the tongue (at least 2 minutes) followed by swallowing the residue. The treatment regimen comprised the following: day 1---1 tablet 100 IR (index of reactivity); day 2---2 tablets 100 IR; and day 3 to day 120---1 daily tablet 300 IR. Blood samples were collected immediately before initial treatment (May 2014) and after the first 4 months of treatment (September 2014), followed by annual collections in May 2015 and May 2016 (prior to commencement of 2nd and 3rd courses of SLIT), and May 2017 (Figure [1](#all14073-fig-0001){ref-type="fig"}A).

![Study design and clinical parameters of allergic rhinitis decreased after SLIT. A, Timeline of SLIT for grass pollen allergy between May 2014 and 2017. Time points indicate blood sampling. B, Allergic rhinitis symptoms by visual analog scale measured during peak pollen season. C, Wheal diameter (in mm) from skin prick test (SPT) with RGP. D, Fractional exhaled nitric oxide (FeNO) measured immediately prior to starting SLIT. E, Total IgE in serum. Each dot represents one individual; red lines indicate median values. Statistical analysis was performed between baseline and each follow‐up time point to assess changes induced by SLIT using the Wilcoxon signed‐rank test; \**P* \< .05, \*\**P* \< .01, and \*\*\**P* \< .001](ALL-75-1121-g001){#all14073-fig-0001}

2.2. Participant characteristics {#all14073-sec-0009}
--------------------------------

Participants were recruited from The Alfred Hospital Allergy Clinic, Melbourne, Victoria, Australia. All had well‐characterized moderate‐to‐severe seasonal allergic rhinitis (plus or minus asthma) due to RGP allergy with positive serum RGP‐specific IgE (≥0.35 kU/L; ImmunoCAP, Phadia). Exclusion criteria were a co‐existing immunodeficiency, previous immunotherapy within the last 5 years, ongoing immunotherapy with other allergens, and treatment with continuous oral corticosteroids and/or β‐blockers. The use of usual medications for allergic rhinitis was permitted, including antihistamines and topical corticosteroids. Alfred Hospital Research and Ethics Committee approval and written informed consent from each participant were obtained prior to inclusion (project number 514/13). Twenty‐nine participants (12 males) were recruited for treatment, with a mean age of 35 years (range 18‐59 year) and mean serum RGP‐specific IgE of 52 kU/L. Five withdrew after the first (baseline) time point (n = 4 tongue swelling, upset stomach; n = 1 failed to attend) leaving 24 participants who commenced SLIT (Table [S1](#all14073-sup-0004){ref-type="supplementary-material"}). At subsequent time points, three participants failed to attend after 4 months of treatment and a further seven participants were excluded after 1 year (n = 2 opted to receive SCIT, n = 2 opted to receive sublingual drops, and n = 3 withdrew). Blood samples for serum and flow cytometric analysis were obtained from n = 24 patients in May 2014 prior to starting SLIT, n = 24 in September 2014, n = 21 in May 2015, n = 14 in May 2016, and n = 14 in May 2017. Details on sample numbers for each analysis are included in Table [S2](#all14073-sup-0004){ref-type="supplementary-material"}. A further 5 RGP‐allergic subjects who did not receive SLIT (ie, received usual medication alone) were included as untreated patients at baseline and 4 months.

2.3. Clinical parameters of allergic rhinitis {#all14073-sec-0010}
---------------------------------------------

Allergic rhinitis symptoms during the peak RGP season were recorded by the participants using a visual analog score (VAS; scale, 0‐100). Fractional exhaled nitric oxide (FeNO, in parts per billion \[ppb\]; HypoAirFeNO) was measured according to the manufacturer\'s instructions (NIOX, Uppsala, Sweden). FeNO was measured immediately before the start of SLIT therapy outside of the grass pollen season to minimize effects of daily fluctuations in pollen levels.

2.4. Quantification of serum total IgE and allergen‐specific IgE, IgG~2~, and IgG~4~ {#all14073-sec-0011}
------------------------------------------------------------------------------------

Serum total IgE, RGP‐specific‐IgE, and ‐IgG~4~ levels were measured by ImmunoCAP. Serum RGP‐specific IgG~2~ antibodies were measured by in‐house ELISA, as described previously.[44](#all14073-bib-0044){ref-type="ref"} Briefly, ELISA plate wells were coated with an aqueous RGP extract (Stallergenes Greer), blocked with 2% bovine serum albumin in PBS (Sigma‐Aldrich), and incubated with serial dilutions of serum samples. Separate wells were coated with serial dilutions of purified human IgG~2~ (Sigma‐Aldrich, \#I5404) to generate a standard curve for quantification of IgG~2~ in serum samples. Bound IgG~2~ was detected using biotinylated anti‐hIgG~2~ (clone HP6002; Thermo Scientific) followed by Pierce High Sensitivity Streptavidin‐HRP (Thermo Scientific). ELISA was developed using TMB (Thermo Scientific), and the reaction stopped with 1 mol/L HCl. Absorbance (OD 450 nm) was measured using a FLUOstar Optima plate reader (BMG Labtech).

2.5. In vitro RGP stimulation of PBMC, Treg staining, and measurement of cytokines {#all14073-sec-0012}
----------------------------------------------------------------------------------

PBMC were isolated by Ficoll‐paque density centrifugation. Fresh PBMC were used for in vitro culture, and the remaining cells stored in liquid nitrogen. PBMC were labeled with CFSE (0.5 µmol/L CFSE/10^7^ PBMC; Molecular Probes) and cultured with an aqueous RGP extract (50 μg/mL; Stallergenes Greer) or tetanus toxoid (20 Lfu/mL; Statens Serum Institut, Copenhagen, Denmark). On day 7, cells were stained with CD4‐PE Cy7, CD25‐PE (both from BD Biosciences), FoxP3‐APC (eBioscience), and aqua live/dead dye (Life Technologies). The Treg gating strategy is shown in Figure [S1](#all14073-sup-0004){ref-type="supplementary-material"}. Data were acquired using an LSR‐II flow cytometer (BD Biosciences).

The levels of IFN‐γ, IL‐5, IL‐10, and IL‐13 in 7‐day culture supernatants were determined using a Luminex human premixed multi‐analyte kit (R&D Systems Inc) according to the manufacturer\'s instructions. Due to changes in IL‐5 production observed after 3 years of SLIT, IL‐13 was also assessed at the same time point to further investigate Th2 cytokine production. Tetanus toxoid was included as a control antigen to determine RGP specificity. "No antigen" values were subtracted from test values.

2.6. B‐cell subset analysis by flow cytometry {#all14073-sec-0013}
---------------------------------------------

One million thawed PBMC were incubated with 11‐color antibody cocktails against B‐cell markers for 15 minutes at room temperature in 100 µL total volume (Table [S](#all14073-sup-0004){ref-type="supplementary-material"}3). Flow cytometric analyses were performed on a 4‐laser LSRFortessa (BD Biosciences), and data were analyzed using FACSDiva V8.0 (BD Biosciences). B‐cell subsets were defined as described previously.[41](#all14073-bib-0041){ref-type="ref"}, [45](#all14073-bib-0045){ref-type="ref"}, [46](#all14073-bib-0046){ref-type="ref"} Briefly, within the CD19^+^ B‐cell population, the proportions were determined of plasmablasts (CD27^+^CD38^high^), transitional (CD27^−^CD38^high^), naive mature (CD27^−^IgM^+^IgD^+^), natural effector memory B cells (CD27^+^IgM^+^IgD^+^), and IgM‐only memory B cells (CD27^+^IgM^+^IgD^--^). Furthermore, we analyzed Ig switched CD27^−^CD38^dim^ and CD27^+^CD38^dim^ memory B cells expressing IgA, IgE, IgG, or each of the 4 IgG subclasses.

2.7. Molecular analysis of Ig gene rearrangements {#all14073-sec-0014}
-------------------------------------------------

RNA was isolated from PBMC from a limited cohort of 5 subjects treated with SLIT (Table EI; patient no. 1, 11, 13, 15, and 19) with a GenElute mammalian RNA kit (Sigma‐Aldrich) and reverse transcribed to cDNA with random primers (Invitrogen Life Technologies, Waltham, MA). Rearranged IgG transcripts were amplified in a multiplex PCR approach using 4 different IGHV family leader forward primers in combination with an *IGHG*‐consensus reverse primer.[47](#all14073-bib-0047){ref-type="ref"} PCR products were cloned into a pGEMT easy vector (Promega), amplified by colony PCR, and sequenced by the Micromon facility of Monash University on an Applied Biosystems 3730s DNA Analyzer (Thermo Scientific). Obtained sequences were analyzed using the IMGT database (<http://www.imgt.org>) to assign the *IGHV*, *IGHD,* and *IGHJ* gene alleles and to identify SHM. For each unique clone, the position and frequency of mutations were determined within the entire *IGHV* gene (FR1‐CDR1‐FR2‐CDR2‐FR3). SHM was determined as variations on the best‐matched V‐gene and represented as the percentage of mutations of the total sequenced V‐gene nucleotides. The IgG subclasses were determined using the IGH reference sequence (NG_001019).

2.8. Statistical analysis {#all14073-sec-0015}
-------------------------

Differences in symptom scores, serum Ig values, cytokines, and B‐ and T‐cell subsets before, during, and after treatment were analyzed with the Wilcoxon signed‐rank test. All analyses were two‐tailed, and differences were considered statistically significant if *P*‐values were \<.05. Due to missing values at year 1, 2, and 3 measures, it was not possible to use repeated measures ANOVA. Therefore, we performed pairwise analysis between time point 0 and each follow‐up sample. Differences in IgG subclass usage of unique *IGH* transcripts were statistically analyzed with the chi‐squared test. Statistical analysis was performed using GraphPad Prism software, version 7.01 (GraphPad Software).

3. RESULTS {#all14073-sec-0016}
==========

3.1. SLIT reduces symptoms of allergic rhinitis {#all14073-sec-0017}
-----------------------------------------------

To study the clinical effects of SLIT, we assessed the severity of symptoms for allergic rhinitis using a VAS. Before the start of treatment, participants reported a median VAS of 80 mm for the 2013 pollen season (Figure [1](#all14073-fig-0001){ref-type="fig"}B). In the first pollen season after commencing SLIT, participants experienced fewer symptoms (median VAS 40 mm, *P* \< .001), and these remained low for the second and third seasons following repeat SLIT courses (median VAS 20 mm at 2 years, *P* \< .001; median VAS 35 mm at 3 years, *P* \< .01), confirming sustained clinical efficacy.

The level of RGP sensitization was monitored by skin prick tests (SPT) with wheal diameters (mm) positively correlating with symptoms of allergic disease.[48](#all14073-bib-0048){ref-type="ref"} SLIT significantly decreased SPT wheal diameter in response to SPT with RGP extract within 1 year of commencing therapy (Figure [1](#all14073-fig-0001){ref-type="fig"}C). Wheal size remained low on retesting after the third year of SLIT. In addition, the severity of airway inflammation and bronchial hyperreactivity was assessed by measurement of FeNO.[49](#all14073-bib-0049){ref-type="ref"}, [50](#all14073-bib-0050){ref-type="ref"} SLIT significantly decreased FeNO from baseline at 1, 2, and 3 years after commencing SLIT (Figure [1](#all14073-fig-0001){ref-type="fig"}D). The significant decreases in SPT wheal diameter and FeNO were consistent with decreased symptoms of allergic rhinitis 1 year after commencing treatment as well as after the second and third successive years of SLIT. The reduction in VAS and FeNO after SLIT did not correspond with any changes in total serum IgE levels (Figure [1](#all14073-fig-0001){ref-type="fig"}E).

3.2. Induction of RGP‐specific Treg and IL‐10 production following SLIT {#all14073-sec-0018}
-----------------------------------------------------------------------

Successful AIT has been associated with proliferation of allergen‐specific Treg.[50](#all14073-bib-0050){ref-type="ref"} To assess Treg proliferation in response to allergen, we stimulated PBMC with RGP and measured the proliferation of activated Treg (CD4^+^CD25^+^FoxP3^+^) using CFSE. RGP‐induced proliferation of Treg was enhanced by SLIT after 4 months and remained raised throughout subsequent years (Figure [2](#all14073-fig-0002){ref-type="fig"}A).

![Sublingual immunotherapy (SLIT) alters in vitro Treg proliferation and cytokine production in response to RGP. PBMC stimulated with RGP were assessed for A, Treg proliferation and production of B, IL‐10, C, IFN‐γ, and D, IL‐5 were determined for all patients included at *t* = 0, 1, 2, 3 y. E. Paired analysis of IL‐5 and F. IL‐13 at *t* = 0 and *t* = 3 y. The lower limit of detection of IL‐10 levels (0.5 pg/mL) in panel B is depicted by a dashed line and datapoints representing undetectable levels are placed below it. Statistical analysis was performed between baseline and each follow‐up time point to assess changes induced by SLIT using the Wilcoxon signed‐rank test; \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 and \*\*\*\**P* \< .0001](ALL-75-1121-g002){#all14073-fig-0002}

Given the role of cytokines in skewing T‐cell responses, we quantified IL‐5, IL‐10, IL‐13, and IFN‐γ production from RGP‐stimulated PBMC. After 3 years of SLIT, T cells produced significantly more IL‐10 and IFN‐γ and significantly less IL‐5 and IL‐13 (Figure [2](#all14073-fig-0002){ref-type="fig"}B‐E). SLIT did not alter the PBMC cytokine response to tetanus toxoid (Figure [S](#all14073-sup-0004){ref-type="supplementary-material"}2). Taken together, the data from our study suggest SLIT enhances Treg response to allergen within 4 months without impacting the Treg response to other antigens. Furthermore, SLIT may alter the Th1/Th2 cytokine profile away from pro‐allergic Th2 cytokines toward a regulatory and Th1‐biased response.

3.3. Increased IgG~4~ serum levels and IgG~4~ ^+^ memory B‐cell frequencies after 4 months SLIT {#all14073-sec-0019}
-----------------------------------------------------------------------------------------------

To study the short‐term effects of SLIT on the immune system, we analyzed serum Ig levels and B‐cell subsets before and directly after the first 4 months of therapy. The gating strategies for flow cytometric detection of memory B cells expressing the four IgG subclasses are shown in Figure [3](#all14073-fig-0003){ref-type="fig"}A. We observed that after 4 months of immunotherapy, RGP‐specific serum IgG~2~ increased from a median of 2.46 to 5.08 μg/mL (Figure [3](#all14073-fig-0003){ref-type="fig"}B). Furthermore, all participants showed an increase in RGP‐specific serum IgG~4~ from a median of 0.37 μg/mL pretreatment to 1.16 μg/mL post‐treatment after 4 months of SLIT. This was accompanied by a significant increase in the frequency of IgG^+^ memory B cells (CD19^+^CD38^dim^) expressing IgG~4~ (Figure [3](#all14073-fig-0003){ref-type="fig"}C). The increase in the IgG~4~ ^+^ memory B‐cell frequencies was not directly correlated with the increase in RGP‐specific serum IgG~4~ (*p* \> .05). SLIT did not change IgE^+^ memory B‐cell frequencies (Figure [3](#all14073-fig-0003){ref-type="fig"}D). However, the increase in IgG~4~ ^+^ memory B cells resulted in a significantly higher IgG~4~ ^+^/IgE^+^ memory B‐cell ratio following 4 months of treatment (Figure [3](#all14073-fig-0003){ref-type="fig"}E). The frequencies of all other B‐cell subsets, including transitional, naive mature, memory, and plasmablasts, remained unchanged after 4 months of SLIT (Figure [S](#all14073-sup-0004){ref-type="supplementary-material"}3). Thus, 4 months SLIT quite specifically affected allergen‐specific IgG~4~ serum levels and the frequencies of IgG~4~‐expressing memory B cells.

![RGP‐specific IgG~4~ and IgG~4~ ^+^:IgE^+^ memory B‐cell ratio increased after a 4‐mo course of SLIT. A, Gating strategy for Ig isotype and IgG subclass‐expressing memory B cells by flow cytometry. B, RGP‐specific IgG~2~ and IgG~4~ in sera and C, proportion of IgG~2~ ^+^ and IgG~4~ ^+^ memory B cells as a percentage of IgG^+^ population after 4 mo of SLIT. D, Proportion of IgE^+^ memory B cells as a percentage of total CD19^+^ B cells after 4 mo of SLIT. E, Ratio of IgG~4~ ^+^ to IgE^+^ B‐cell percentages after 4 mo of SLIT (from C and D). Each dot represents one individual; red lines indicate median values. Statistical analysis was performed between baseline and each follow‐up time point to assess changes induced by SLIT using the Wilcoxon signed‐rank test. \**P* \< .05 and \*\*\*\**P* \< .0001](ALL-75-1121-g003){#all14073-fig-0003}

3.4. SLIT has persistent long‐term effects on IgG~2~ and IgG~4~ memory B cells {#all14073-sec-0020}
------------------------------------------------------------------------------

In addition to short‐term effects of SLIT, we studied the longer‐term effects of SLIT, that is, 1, 2, and 3 years after the start of the first treatment course. SLIT did not significantly alter serum RGP‐specific IgE levels (Figure [4](#all14073-fig-0004){ref-type="fig"}A). RGP‐specific IgG~2~ levels increased after a total of 3 courses of SLIT (Figure [4](#all14073-fig-0004){ref-type="fig"}A). RGP‐specific IgG~4~ increased after each consecutive course of treatment at 1, 2, and 3 years (Figure [4](#all14073-fig-0004){ref-type="fig"}A). Similar to RGP‐specific IgE and IgG~2~ antibodies, frequencies of IgE^+^ memory B cells were unchanged by SLIT, while IgG~2~ ^+^ memory B cells were significantly increased 3 years after commencing SLIT (Figure [4](#all14073-fig-0004){ref-type="fig"}B). Frequencies of IgG~4~ ^+^ memory B cells were increased 2 years after commencing SLIT.

![Persistent increase in IgG~4~ and late rise in IgG~2~ after three 4‐mo SLIT courses. A, RGP‐specific IgE, IgG~2~ and IgG~4~ in serum. B, Proportions of IgE^+^, IgG~2~ ^+^, and IgG~4~ ^+^ memory B cells in peripheral blood. IgE^+^ memory B cells presented as a percentage of CD19^+^ B cells. IgG~2~ ^+^ and IgG~4~ ^+^ memory B cells presented as a percentage of IgG^+^ memory B cells. Baseline data for IgE^+^ and IgG4^+^ B cells are the same as those in Figure [3](#all14073-fig-0003){ref-type="fig"}C and D. Statistical analysis was performed between baseline and each follow‐up time point to assess changes induced by SLIT using the Wilcoxon signed‐rank test; \**P* \< .05 and \*\**P* \< .01](ALL-75-1121-g004){#all14073-fig-0004}

3.5. Molecular analysis of Ig gene rearrangements {#all14073-sec-0021}
-------------------------------------------------

Given that SLIT increased IgG~2~ and IgG~4~ antibodies and memory B‐cell proportions, we investigated whether these changes were reflected in the proportions of unique IgG transcripts from blood B cells for a subgroup of 5 participants with an increased percentage of IgG~2~ ^+^ memory B cells after SLIT. Median frequencies of somatic hypermutations did not differ between the proximal IgG~1~ and the distal IgG~2~ subclasses (Figure [5](#all14073-fig-0005){ref-type="fig"}A and B) nor were significantly different after 3 years SLIT. However, after 3 years SLIT the relative usage of the IgG~2~ and IgG~4~ subclasses were significantly increased at the expense of IgG~1~ (Figure [5](#all14073-fig-0005){ref-type="fig"}C). Taken together, these data demonstrate that repeat courses of SLIT for grass pollen allergy induce allergen‐specific IgG~2~ and IgG~4~ responses, evidenced by an increase in IgG~2~ ^+^ and IgG~4~ ^+^ B‐cell proportions and skewing toward unique IgG~2~ and IgG~4~ transcripts.

![Sublingual immunotherapy (SLIT) increases frequency of unique IgG2 transcripts. A, Schematics of the human *IGH* locus depicting the positioning of the constant gene regions relative to the rearranged VDJ exon. B, Somatic hypermutation frequencies of unique IgG transcripts obtained from 5 patients before (2014) and after SLIT (2017) and grouped per IgG subclass. C, Relative isotype distribution of unique IgG transcripts. Central number indicates total unique IgG sequences identified. Significance was determined by chi‐squared test; \*\**P* = .0011](ALL-75-1121-g005){#all14073-fig-0005}

4. DISCUSSION {#all14073-sec-0022}
=============

We here report that SLIT for grass pollen allergy not only has long‐term beneficial clinical effects, but also results in sustained systemic effects on the immune system. SLIT induced a rapid and prolonged increase in RGP‐specific serum IgG~4~ accompanied by an increase in the frequency of peripheral blood IgG~4~ ^+^ memory B cells. Furthermore, repeat courses of SLIT resulted in a similar increase in RGP‐specific IgG~2~ in serum corresponding with increased frequency of IgG~2~ ^+^ memory B cells in the blood.

Currently, grass pollen SLIT is recommended as a preseasonal and co‐seasonal course starting 4 months prior to the hay fever season, confirmed by meta‐analyses as clinically effective.[2](#all14073-bib-0002){ref-type="ref"} Yet, long‐term treatment regimens are costly and discourage treatment adherence.[51](#all14073-bib-0051){ref-type="ref"} As patients are exposed to grass pollens during the spring season, we reasoned that a 4 months preseasonal treatment regimen would avoid the risk of adding to excessive and unpredictable allergen loads during the Melbourne Spring. Based on our analysis of symptom scores, this approach is highly effective.[42](#all14073-bib-0042){ref-type="ref"}, [43](#all14073-bib-0043){ref-type="ref"} Prolonged treatment (duration \> 12 months) is known to have beneficial effects on symptom and medication scores.[52](#all14073-bib-0052){ref-type="ref"} The fact that some immunological effects are delayed, only occurring after the second or third treatment year as observed for serum RGP‐specific IgG~2~ levels, or continuing to rise after consecutive treatment as for serum RGP‐specific IgG~4~ levels, supports these premises.

In particular, we observed a marked increase in RGP‐specific IgG. Previously, allergen‐specific immunotherapy, either SCIT or SLIT, has already been demonstrated to result in increased allergen‐specific IgG~4~ serum levels.[53](#all14073-bib-0053){ref-type="ref"}, [54](#all14073-bib-0054){ref-type="ref"} Increased allergen‐specific IgG~4~ has been postulated as one of the explanations for the beneficial effects of immunotherapy and has been observed as a natural effect in beekeepers exposed to bee venom for prolonged periods,[55](#all14073-bib-0055){ref-type="ref"} yet the exact desensitizing effect of specific IgG~4~ in immunotherapy remains unclear. Allergen‐specific IgG~4~ can competitively inhibit IgE from binding to allergens and may subsequently reduce allergic responses by preventing FcεR‐mediated activation of granulocytes.[56](#all14073-bib-0056){ref-type="ref"} Furthermore, IgG~4~ antibody has been proposed to inhibit inflammatory responses by preventing C1q complement activation and binding to the inhibitory receptor FcγRIIb (CD32b).[57](#all14073-bib-0057){ref-type="ref"}, [58](#all14073-bib-0058){ref-type="ref"}

SLIT also increased RGP‐specific IgG~2~ after three consecutive courses of SLIT. This suggests repeated or high‐dose exposure to RGP from SLIT is required to enhance RGP‐specific IgG~2~ beyond that which is generated from annual RGP exposure during the pollen season. Furthermore, sublingual administration of RGP may have preferentially induced an IgG~2~ response not seen from environmental exposure through the airway.

The immune mechanisms by which allergen‐specific IgG~2~ may contribute to the benefits of immunotherapy remain unclear. IgG~2~ has been shown to inhibit histamine release from basophils by activating FcγRIIb and may reduce allergic symptoms by this mechanism.[59](#all14073-bib-0059){ref-type="ref"} In a similar manner to IgG~4~, IgG~2~ may also bind allergen and prevent effector cell degranulation by masking IgE epitopes.

The source of increased serum IgG~2~ and IgG~4~ levels is IgG~2~‐ and IgG~4~‐producing plasma cells, respectively. As the majority of serum IgG is produced by bone marrow residing plasma cells, we were unable to assess these. However, we did assess the more immature plasmablasts in blood, finding that their frequencies were not affected by SLIT. Further characterization of Ig isotypes and IgG subclasses was not possible due to our approach for membrane staining, since the majority of plasmablasts (especially those producing IgG) lack surface Ig expression. Hence, we focused on the analysis of memory B cells, which are abundant in the blood due to their circulatory nature, and their capacity to quickly differentiate into plasma cells in subsequent antigen responses.[60](#all14073-bib-0060){ref-type="ref"}

We observed that SLIT drives increased frequencies of IgG~2~ ^+^ and IgG~4~ ^+^ memory B cells, whereas there was no effect on frequencies of IgE^+^ memory B‐cell subsets. The latter observation can explain the absence of a decline in IgE serum levels as also demonstrated by others.[52](#all14073-bib-0052){ref-type="ref"}, [61](#all14073-bib-0061){ref-type="ref"}, [62](#all14073-bib-0062){ref-type="ref"} Since we observed the increase in IgG~4~ ^+^ memory B cells after 4 months of treatment with SLIT, and before the pollen season, this effect can be directly attributed to the treatment with Oralair^®^. Our observation that frequencies of IgG~4~ ^+^ memory B cells remain increased for at least 3 years can be an explanation for the long‐lasting effects attributed to immunotherapy.[5](#all14073-bib-0005){ref-type="ref"}, [6](#all14073-bib-0006){ref-type="ref"}, [7](#all14073-bib-0007){ref-type="ref"}

Allergen‐specific IgG~2~ and IgG~4~ appear to be robust markers of repeated allergen exposure. Increases in allergen‐specific IgG~2~ and IgG~4~ alongside increased frequency of IgG~2~ ^+^ and IgG~4~ ^+^ memory B cells may arise from class switching of allergen‐specific IgG~1~ ^+^ memory B cells upon repeated exposure to allergen. Sequential Ig class switching can only occur 5'--3' along the *IGH* locus, which is arranged in the following order: IgG~3~ \> IgG~1~ \> IgG~2~ \> IgG~4~ \> IgE \> IgA (Figure [5](#all14073-fig-0005){ref-type="fig"}A). As such, IgG~1~ ^+^ B cells may switch to IgG~2~ or IgG~4~ but not vice versa. In a study of allergen‐specific antibodies in children from birth to 10 years old, IgE responses to aeroallergens were typically preceded by IgG.[63](#all14073-bib-0063){ref-type="ref"} Allergen‐specific IgG^+^ memory B cells may therefore provide a reservoir for switching to IgE that can be induced by repeated exposure to the allergen and subsequently cause allergic sensitization. A similar pathway may give rise to allergen‐specific IgG~2~ and IgG~4~, whereby allergen exposure promotes class switching of allergen‐specific IgG~1~ ^+^ memory B cells to IgG~2~ and IgG~4~. Switching to IgG~2~ and IgG~4~ may help explain why many allergies subside with age, perhaps due to repeated allergen exposure throughout childhood. However, it remains to be determined whether allergen‐specific IgG~2~ and IgG~4~ are indispensable for generating clinical benefit by SLIT in lieu of T cell--mediated tolerance.

In line with previous reports, we observed that proliferation of Treg from patients after SLIT was increased in response to in vitro stimulation with RGP. Previous studies have observed new generation of allergen‐specific Treg, as well as clonal expansion of allergen‐specific Treg in response to AIT.[56](#all14073-bib-0056){ref-type="ref"}, [64](#all14073-bib-0064){ref-type="ref"} Furthermore, we observed that SLIT increased IL‐10 production from RGP‐stimulated PBMC, whereas IL‐13 was diminished. The cytokines IL‐4 and IL‐13 promote Ig class switch recombination (CSR) to IgE, and these are predominantly produced by Th2 cells. In addition to Th2 cytokines, CSR to IgG~4~ is also regulated by IL‐10 which is predominantly secreted by Treg. Our data are consistent with SLIT‐induced proliferation of allergen‐specific Treg, whereby increased IL‐10 production induces Ig class switching of allergen‐specific B cells to IgG~4~. B regulatory cells (Breg) and monocyte‐derived macrophages may also be an alternative source of IL‐10 in our in vitro assay, further enhancing IgG~4~ class switching in response to RGP.[65](#all14073-bib-0065){ref-type="ref"}, [66](#all14073-bib-0066){ref-type="ref"}

In conclusion, our data provide evidence for long‐lasting effects of allergen SLIT on the memory compartment of the immune system. Increased Treg frequencies and increased IL‐10 production were associated with increased frequency of IgG~4~ ^+^ memory B cells and a beneficial shift in the IgG~4~ ^+^/IgE^+^ memory B‐cell ratio, reflecting the increased IgG~4~/IgE antibody fraction in serum and resultant clinically favorable outcome. Moreover, to our knowledge, our study is the first to demonstrate increases in memory B cells expressing IgG~2~ or IgG~4~ following allergen immunotherapy. As IgG~2~ and IgG~4~ have anti‐inflammatory properties and are induced following repeated antigen‐exposure,[41](#all14073-bib-0041){ref-type="ref"} this B‐cell memory compartment is a potential mechanism by which allergen immunotherapy modifies the natural course of disease. In future studies, it would therefore be of interest to examine the functional properties of allergen‐specific B cells, as well as the effector functions of allergen‐specific IgG subclasses.[67](#all14073-bib-0067){ref-type="ref"}
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